Immunovia, Inc has received final approval to begin patient testing for the IMMray PanCan-d test.
The IMMray PanCan-d test is the first blood test on the market dedicated to the early detection of pancreatic cancer.
“We are extremely pleased to have achieved this important milestone and to be able to launch the first non-invasive, highly accurate blood test that can help detect pancreatic cancer in early stages. The IMMray PanCan-d test meets a huge clinical need and our ambition is to make the test available to individuals in all the high-risk groups for pancreatic cancer. As a first step, we will launch the test for the familial/hereditary high-risk group,” says Patrik Dahlen, Immunovia’s CEO.
Read more: Immunovia – On the threshold of commercial launch
Early detection of pancreatic cancer
This approval was received from the Massachusetts Department of Public Health on August 3, 2021. Immunovia, Inc. received its CLIA Certificate of Registration on June 21, 2021.
As a result, Immunovia, Inc. can immediately begin selling the IMMray PanCan-d test for early detection of pancreatic cancer in the US exclusively through their laboratory in Marlborough, Massachusetts.
Photo: Immunovia lab
